SafeRX Pharmaceuticals to Exhibit Alcohol-Resistant Opioid Platform at 2021 FSIPP/FSPMR Annual Conference
SafeRx Pharmaceuticals will be exhibiting details about its groundbreaking alcohol-resistant opioid (ARO) platform at the annual conference co-hosted by the Florida Society of Interventional Pain Physicians (FSIPP) and the Florida Society of Physical Medicine and Rehabilitation (FSPMR).
BOSTON , July 26, 2021 /PRNewswire-PRWeb/ -- SafeRx Pharmaceuticals will be exhibiting details about its groundbreaking alcohol-resistant opioid (ARO) platform at the annual conference co-hosted by the Florida Society of Interventional Pain Physicians (FSIPP) and the Florida Society of Physical Medicine and Rehabilitation (FSPMR). The conference will be held from August 12 through August 15, 2021, in Tampa, Florida.
SafeRx's ARO solution addresses the ever-increasing need in pain management to reduce preventable deaths caused by the consumption of alcohol with the prescribed opioid. The ARO platform combines opioid analgesics with a proven alcohol-deterrent formula known as an ALDI that interferes with the metabolism of alcohol but otherwise remains essentially inactive in the body.
"Our goal is to introduce even more pain practitioners to this innovative solution that can significantly improve the quality and outcomes of the treatment that their patients receive," said Michael Presti, M.D., Ph.D., a Mayo Clinic-trained neurologist and founder-CEO of SafeRX Pharmaceuticals. "In the United States, a life is lost due to combining alcohol with opioid medications every two and a half hours. Our AROs offer high-risk patients a much safer option for pain management, and we're looking forward to sharing our technology with more experts in the field."
According to the CDC, 22.1% of prescription opioid-related deaths occur when a person taking these medications also consumes alcohol; research also shows that long-term opioid patients with a history of alcohol problems are five times more likely to overdose on their medication. During the COVID-19 pandemic, according to the CDC fatal opioid-related overdoses have increased dramatically, possibly associated with an increase in alcohol consumption related to worsening of co-morbid anxiety and depression.
The FSIPP/FSPMR Conference will bring approximately 300 pain practitioners from across the United States, Europe and The Caribbean to Tampa. Exhibitors will present cutting-edge data and information to attendees and provide a forum to interact and discuss evidence-based medicine to improve the quality of care and access to care for patients.
Conference attendees can speak with representatives from SafeRX at a hosted breakfast on Friday, August 13, from 7:00 – 8:00 a.m.; other interested stakeholders are encouraged to reach out directly to the company for more information at [email protected].
About SafeRx Pharmaceuticals:
SafeRx was founded with one mission in mind: to reduce the risk of prescription opioid overdose. The opioid crisis represents one of the greatest national public health emergencies of our time, ravaging communities throughout this country for decades. And unlike COVID, there is no vaccine on the way; there will never be a "silver bullet" for this intricate problem. But SafeRx has developed a solution to a previously unaddressed dimension of the crisis that is responsible for thousands of fatal prescription overdoses every year: the combination of opioids with alcohol. For more information please visit https://saferxpharmaceuticals.com/. Investors can learn more at https://www.investinsaferx.com/.
Contact: Joy Scott
Scott Public Relations
818.610.0270
[email protected]
Media Contact
Maggie Palmer, SafeRx Pharmaceuticals, +1 (503) 419-7677, [email protected]
Maggie Palmer
SOURCE SafeRx Pharmaceuticals
Share this article